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Noninvasive detection of renal allograft inflammation by mea-
surements of mRNA for IP-10 and CXCR3 in urine.
Background. We explored the hypothesis that measurements
of mRNA encoding interferon-inducible protein-10 (IP-10) or
the chemokine receptor CXCR3 in urinary cells offer a noninva-
sive means of elucidating cellular traffic causing acute rejection
of human renal allografts.
Methods. We obtained 63 urine specimens from 58 renal allo-
graft recipients who underwent 63 allograft biopsies to resolve
the basis for graft dysfunction, and 27 additional urine samples
from 24 other patients with stable allograft function. Twenty-
seven of the 63 biopsies were classified as acute rejection, 20 as
other, and 16 as chronic allograft nephropathy. We measured
the levels of transcripts for IP-10 and CXCR3, and a consti-
tutively expressed gene 18S rRNA in the urine specimens and
correlated transcript levels with renal allograft diagnosis.
Results. mRNA levels of IP-10 (P < 0.0001) or CXCR3 (P <
0.0001) but not the levels of 18S rRNA (P = 0.56) predicted
intragraft cellular traffic causing acute rejection. Receiver-
operating characteristic curve analysis demonstrated that acute
rejection can be predicted with a sensitivity of 100% and a speci-
ficity of 78% using the (log-transformed) cutoff value of 9.11
copies of IP-10, and with a sensitivity of 63% and a specificity
of 83% using the cutoff value of 11.59 copies of CXCR3. Im-
munohistologic analysis of allograft biopsies showed exuberant
expression of IP-10 and CXCR3 during acute rejection whereas
both were absent in grafts with stable function.
Conclusion. Our investigation demonstrates that intragraft
cellular events associated with acute rejection of human renal
allografts can be noninvasively identified by measurements of
mRNA for IP-10 and CXCR3 in urinary cells.
Chemokines constitute a family of structurally related
small-molecular-weight cytokines which contribute to tis-
Key words: rejection, chemokines, mRNA.
Received for publication October 29, 2003
Accepted for publication January 7, 2004
C© 2004 by the International Society of Nephrology
sue morphogenesis, hematopoiesis, cell proliferation and
apoptosis, but their roles in leukocyte trafficking and re-
cruitment during inflammatory responses have signifi-
cance for renal medicine including renal transplantation
[1, 2]. Studies in animal models have shown that all of the
50 known chemokines and their 20 receptors can be ex-
pressed at some stage during allograft rejection [3]. How-
ever, certain chemokine/chemokine receptor pathways
have proven critical in the rejection of vascularized allo-
grafts in rodent models [4–7]. Comparative investigations
have shown the particular importance of the chemokine
receptor, CXCR3, in mediating host alloresponses and
graft destruction [5]. Targeting of CXCR3 by homologous
recombination [5], neutralizing monoclonal antibodies
[5], or small molecule inhibitor [8], markedly prolonged
cardiac allograft survival. Moreover, targeting of the
CXCR3 chemokine ligand, interferon-inducible protein-
10 (IP-10), by homologous recombination or monoclonal
antibody in wild-type recipients, was also of therapeutic
importance [9]. Both IP-10 and CXCR3 have also been
implicated in human cardiac allograft rejection by their
intragraft expression during episodes of acute rejection
[10–12], leading to preclinical trials of a neutralizing an-
tihuman CXCR3 monoclonal antibody and a CXCR3
small molecule antagonist in nonhuman primate renal
allograft recipients [13].
Acute rejection of a renal allograft is suggested by clin-
ical features such as loin pain, fever, and oliguria and is
currently established by histologic findings within a per-
cutaneous renal biopsy [14]. While invasive and prone
to sampling errors, renal transplant biopsies are reason-
ably safe and a standardized approach to their assessment
has benefited clinical trials [15, 16], although surprising
and significant interobserver variations in diagnosis have
been noted [17]. The invasive nature of renal biopsy is
particularly significant in the pediatric patient since the
renal transplant is often placed in an intra-abdominal
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Table 1. Study cohorts for the measurement of mRNAs in urinary cells
Acute Other Chronic allograft Stable graft
rejectiona findingsa nephropathya functiona
Number of allograft recipients (N = 82) 24 19 15 24
Age (mean ± SD) years 37 ± 11 49 ± 10 51 ± 12 47 ± 13
Gender male/female 10/14 14/5 8/7 19/5
Graft donor source living/cadaver 13/11 6/13 3/12 15/9
Number of allograft biopsies (N = 63) 27 20 16 0
Number of urine samples (N = 90) 27 20 16 27
aThe diagnoses of acute rejection, other findings, and chronic allograft nephropathy were made by histologic evaluation of renal-allograft biopsy specimens. The
clinical diagnosis of stable graft function was based on the finding that serum creatinine levels either had decreased or had not increased by more than 0.2 mg/dL during
the 7 days before and the 7 days after the urine samples were collected.
Table 2. Sequence and location of oligonucleotide primers and fluorogenic probesa
Gene Accession number Sequence
IP-10 NT 022760 Sense 5′-ATTTTGTCCACGTGTTGAGATCA-3′
Antisense 5′-TGGCCTTCGATTCTGGATTC-3′
Probe 5′-FAM-GACATCTCTTTCTCACCCTTCTTTTTCATTGTAGCA-TAMRA-3′
CXCR3 NM 00154 Sense 5′-ACCCAGCAGCCAGAGCAC-3′
Antisense 5′-CAACCTCGGCGTCATTTAGC-3′
Probe 5′-FAM-CTTGGTGGTCACTCACCTCAAGGACCAT-TAMRA-3′
18S rRNA K 03432 Sense 5′-GCCCGAAGCGTTTACTTTGA-3′
Antisense 5′-TCCATTATTCCTAGCTGCGGTATC-3′
Probe 5′-FAM-AAAGCAGGCCCGACGGCGG-TAMRA-3′
aThe probes for interferon-inducible protein-10 (IP-10) mRNA, CXCR3 mRNA, and 18S rRNA were labeled with 6-carboxy-fluorescein (FAM) at the 5′ end and
with 6-carboxy-tetramethylrodamine (TAMRA) at the 3′ end. FAM functioned as the reporter dye and TAMRA as the quencher dye.
location making the biopsy procedure challenging.
mRNA profiling of allograft biopsy specimens, includ-
ing the use of DNA microarray profiling for analysis of
human renal biopsies, may refine the mechanistic infor-
mation gleaned from biopsy specimens [18–21], but such
analysis requires invasive tissue sampling as well.
An important goal for the transplant community is the
development of noninvasive probes for the assessment of
renal allografts. Radermacher et al [22] recently showed
that use of Doppler ultrasonography to prospectively
measure the renal segmental arterial resistance in more
than 600 renal transplant recipients allowed prediction of
long-term allograft function even more accurately than
did measurements of glomerular filtration rates (GFR).
With respect to noninvasive diagnosis of acute rejection,
the most serious complication of organ transplantation,
Vasconcellos et al [23] showed that heightened expres-
sion of perforin, granzyme B, and fas ligand mRNA in
peripheral blood leukocytes is a correlate of acute re-
nal allograft rejection, particularly when two or more of
these genes are up-regulated [23]. We reported that mea-
surement of mRNAs for cytotoxic proteins perforin and
granzyme B in urinary cells offers a noninvasive means
of diagnosing acute rejection of renal allografts [24].
In light of preclinical data that IP-10 and CXCR3 par-
ticipate in the immigration of alloreactive cells in to the
allograft as well as in the development of acute rejection,
we designed and developed kinetic quantitative poly-
merase chain reaction (PCR) assay for the measurements
of transcripts for IP-10 and CXCR3 in urinary cells and in-
vestigated the hypothesis that measurements of mRNAs
encoding IP-10 or CXCR3 in urinary cells noninvasively
identify critical cellular traffic causing acute rejection of
human renal allografts.
METHODS
Collection of urine samples and kidney biopsies
We obtained 90 urine specimens from 82 kidney trans-
plant recipients (Table 1). Fifty-eight of the 82 patients
underwent 63 allograft biopsies to resolve the basis for
graft dysfunction and 63 urine specimens were collected
within 24 hours of the core needle biopsy of the allo-
graft. All biopsy specimens were evaluated by a single
pathologist who was unaware of the results of molecu-
lar studies. Using the Banff 97 classification, 27 of the
63 biopsy specimens were classified as acute rejection,
20 specimens as other histologic findings (other), and 16
biopsies as chronic allograft nephropathy. The remain-
ing 27 urine samples were from 24 patients who were
classified as having stable allograft function after trans-
plantation. In these patients, the serum creatinine lev-
els either had decreased or had not increased by more
than 0.2 mg/dL during the 7 days before and 7 days after
urine collection. Immunosuppression consisted of either
a cyclosporine-based or tacrolimus-based regimen, and
the acute rejection episodes were treated with a course
of intravenous methylprednisolone [24]. Antilymphocyte
antibodies (CD3 monoclonal antibodies or antithymo-
cyte globulin) were given to patients who had an episode
of glucocorticoid-resistant acute rejection.
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Isolation of RNA and design of primers and probes
Urine was centrifuged at 10,000g for 30 minutes at 4◦C.
RNA was isolated from the cell pellet using an RNeasy
minikit (Qiagen, Chatsworth, CA, USA), quantified and
reverse-transcribed to cDNA as described [24, 25]. We de-
signed and synthesized oligonucleotide primers and fluo-
rogenic probes for the measurement of IP-10 and CXCR3
with the use of kinetic quantitative PCR assay (Table 2).
We also designed and developed primers and probes for
the quantification of 18S ribosomal RNA (rRNA).
Kinetic quantitative PCR assay
mRNA levels of IP-10 and CXCR3 and the levels of
18S rRNA were measured with the use of ABI Prism
7700 sequence detection system (PE Biosystems, Foster
City, CA, USA). PCR reaction for each sample was set
up in duplicate as a 25 lL reaction volume using 12.5 lL
TaqMan Universal PCR Master Mix, 2.5 lL of 1:10
diluted (1:1000 for 18S rRNA measurement) template
cDNA, 300 nmol/L of primers, and 200 nmol/L of probe.
PCR amplification included an initial incubation at 50◦C
for 2 minutes and denaturation at 95◦C for 10 minutes.
This was followed by heating at 95◦C for 15 seconds and
60◦C for 60 seconds repeated for 40 cycles. The PCR am-
plicon for 18S rRNA was prepared, quantified, and used
for developing standard curves. The standard curves were
based on the principle that a plot of the log of the initial
target copy number of a standard versus threshold cy-
cle results in a straight line. mRNA levels in the samples
were expressed as number of copies per microgram of
total RNA isolated from the urinary cells.
Immunohistology
We localized IP-10 and CXCR3 within renal biopsies in
those patients with either stable function posttransplant
or acute rejection. Cryostat sections were labeled us-
ing monoclonal antibodies to IP-10, CXCR3, or isotype-
matched controls (Pharmingen, San Diego, CA, USA)
and an EnVision immunoperoxidase kit (Dako, Carpin-
teria, CA, USA), as described [26].
Statistical analysis
We used GraphPad Prism 3.03 Statistical Software for
Windows (GraphPad Software, San Diego CA, USA).
The levels of mRNA for IP-10 and CXCR3 and 18S rRNA
levels deviated significantly from a normal distribution
(P < 0.0001), which was substantially reduced by use of
a log transformation. The natural log mRNA levels were
used as the dependent variable in a one-way analysis of
variance (ANOVA) to test for any differences among
the various diagnostic groups. Dunnett’s test for multi-
ple comparisons was then used to control the risk of a
type I error while comparing the mRNA levels in the
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Fig. 1. Levels of mRNA and rRNA in urinary cells. Box and whisker
plots show the 10th, 25th, 50th (median), 75th, and 90th percentile values
(log) for interferon-inducible protein-10 (IP-10) mRNA (A), CXCR3
mRNA (B), and 18S rRNA (C) in urine samples from patients classi-
fied as having an episode of acute rejection, other findings on allograft
biopsy, chronic allograft biopsy, or stable course after renal transplan-
tation. The levels of IP-10 mRNA (P < 0.0001) and CXCR3 mRNA
(P < 0.0001), but not those of 18S rRNA (P = 0.56), were significantly
higher in patients with an episode of acute rejection than in the patients
in the other diagnostic groups [P value by one-way analysis of variance
(ANOVA)]. Values in parenthesis are the numbers of urine samples.
acute rejection group with those in the “other,” chronic
allograft nephropathy, and stable posttransplant groups.
The relationship between the levels of mRNA for IP-
10 and CXCR3 was estimated with Pearson’s correla-
tion. Receiver-operating characteristic curve analysis of
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Table 3. Levels of mRNA (copies/lg of total RNA) in urinary cells of patients postrenal transplantationa
Acute rejection Other findings Chronic allograft Stable graft
Type of mRNA (N = 27)b (N = 20) nephropathy (N = 16) function (N = 27) P valuec
IP-10 11.9 ± 0.3 9.0 ± 0.6 8.7 ± 0.3 8.9 ± 0.3 <0.0001
CXCR3 11.7 ± 0.3 8.3 ± 0.9 9.9 ± 0.5 7.5 ± 0.7 <0.0001
18S rRNA 24.6 ± 0.3 24.0 ± 0.4 24.3 ± 0.4 24.3 ± 0.3 0.56
aCopies of mRNA and rRNA were measured with the use of gene-specific primers and probes by real-time polymerase chain reaction (PCR) assay. Plus-minus
values are mean (±SE) of the natural logarithm of mRNA and rRNA copy number.
bValues in parentheses are the numbers of urine samples.
cP values were calculated with the use of log-transformed mRNA copy numbers as the dependent variable in one-way analysis of variance (ANOVA). Dunnett’s test
was then used to compare the mRNA copy numbers in samples showing acute rejection with the mRNA copy numbers in each of the three other groups of samples.
It showed that copy number of interferon-inducible protein-10 (IP-10) mRNA in urinary cells obtained during an episode of acute rejection was significantly higher
than those in specimens with other findings (P < 0.01), chronic allograft nephropathy (P < 0.01), or stable function (P < 0.01). Dunnett’s procedure showed that the
copy number of CXCR3 mRNA in urinary cells obtained during an episode of acute rejection was significantly higher than those in specimens with other findings (P <
0.01) or stable function (P < 0.01) but not in specimens with chronic allograft nephropathy (P > 0.05). None of the pair-wise comparisons copy numbers of 18S rRNA
in urinary cells were significant.
mRNA levels was used to determine cutoff values that
maximized the combined sensitivity and specificity for
distinguishing patients with acute rejection from those
without acute rejection. The area under the curve was
calculated, and sensitivity and specificity at the selected
cutoffs were determined.
RESULTS
mRNA levels in urinary cells
The level of IP-10 mRNA was higher in urinary cells
from patients with acute rejection as compared with those
without acute rejection. Figure 1A and Table 3 show IP-
10 mRNA levels in urinary cells from the patients with
an episode of acute rejection, patients with other find-
ings on allograft biopsy, patients with biopsy evidence
of chronic allograft nephropathy, and patients with sta-
ble graft function after renal transplantation. The nat-
ural log transformed IP-10 mRNA levels were used as
the dependent variable in a one-way ANOVA to test for
any differences among the four diagnostic groups. IP-10
mRNA levels, measured during an episode of acute rejec-
tion, were significantly higher compared with the three
other three diagnostic groups (P < 0.0001). Dunnett’s
test for multiple comparisons demonstrated that IP-10
mRNA levels in urinary cells obtained during acute re-
jection were significantly higher than in those classified as
“other” (P < 0.01), chronic allograft nephropathy (P <
0.01), or stable posttransplant group (P < 0.01).
The level of CXCR3 mRNA was also higher in uri-
nary cells from patients with acute rejection as compared
with those without acute rejection (Fig. 1B) (Table 3).
CXCR3 mRNA levels, measured during an episode of
acute rejection, were significantly higher compared with
the three other three diagnostic groups (P < 0.0001,
one-way ANOVA). Dunnett’s test showed that CXCR3
mRNA levels in urinary cells obtained during an episode
of acute rejection were significantly higher than those
classified as “other” (P < 0.01) or stable posttransplant
(P < 0.01) but not chronic allograft nephropathy (P >
0.05).
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Fig. 2. Coordinated expression of mRNAs for interferon-inducible
protein-10 (IP-10) and CXCR3 in urinary cells. The relationship be-
tween the levels of IP-10 mRNA and CXCR3 mRNA in urinary cells
was estimated with the Pearson correlation, and was significant at P <
0.0001.
Figure 1C and Table 3 show that, in contrast to the
levels of mRNA for CXCR3 or IP-10, the levels of con-
stitutively expressed 18S rRNA do not vary significantly
among the four diagnostic categories (P = 0.56).
We used Pearson’s correlation to estimate the relation-
ship between the levels of mRNA for IP-10 and CXCR3.
Our evaluation revealed a significant and positive corre-
lation between the levels of expression of IP-10 mRNA
and CXCR3 mRNA in urinary cells (Fig. 2) (r = 0.57, P <
0.0001).
Receiver-operating characteristic curve analysis
of mRNA levels
The receiver-operating characteristic curves (Fig. 3)
show the true positive fractions (sensitivity) and false
positive fractions (1-specificity) for various cut points for
mRNA levels of IP-10 (Fig. 3A), CXCR3 (Fig. 3B), and
18S rRNA (Fig. 3C). The natural log-transformed cut
point (threshold) that maximized the combined sensitiv-
ity and specificity for IP-10 mRNA was 9.11 copies/lg
total RNA (Fig. 3A). At this threshold, the sensitivity
was 100% and the specificity was 78% (P < 0.0001). The
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Fig. 3. Receiver-operating characteristic curve of mRNA and rRNA
levels. The fraction of true positive results (sensitivity) and false positive
results (1-specificity) for interferon-inducible protein-10 (IP-10) mRNA
levels (A), CXCR3 mRNA levels (B), and 18S rRNA levels (C), as
markers of acute rejection are shown. The calculated area under the
curve was 0.903 for IP-10 mRNA levels, 0.762 for CXCR3 mRNA levels,
and 0.574 for 18S rRNA levels. A value of 0.5 is no better than expected
by chance, and a value of 1.0 reflects a perfect indicator.
calculated area under the curve was 0.903 (95% CI 0.824
to 0.982). The cut point that maximized the combined
sensitivity and specificity for CXCR3 mRNA was 11.59
copies/lg total RNA (Fig. 3B). At this threshold, the sen-
sitivity was 63% and the specificity was 83% (P < 0.0001).
The calculated area under the curve was 0.762 (95% CI
0.6444 to 0.881).
Figure 3C shows the receiver-operator characteristic
curve for 18S rRNA with respect to presence or absence
of acute rejection. 18S rRNA levels did not discriminate
acute rejection from other renal diagnoses and the cal-
culated area under the curve was 0.574 (95% CI 0.429 to
0.715).
Localization of IP-10 protein and CXCR3 protein within
renal allograft biopsies
We performed immunohistochemical studies of renal
allograft biopsy specimens from patients with stable renal
function and patients with acute rejection to investigate
whether IP-10 and CXCR3 are expressed in a differen-
tial fashion in the allograft biopsy specimens. In accor-
dance with mRNA data, only minor staining for IP-10,
localized to sparsely distributed interstitial cells, and no
CXCR3 expression was observed in the allograft biopsy
specimen classified as no acute rejection (Fig. 4C and E);
however, dense staining of tubular cells and infiltrating
mononuclear cells for IP-10 was observed in the biopsy
specimen obtained during an episode of acute rejection
(Fig. 4D), and CXCR3 was localized to host mononuclear
cells, including leukocytes in areas of tubulitis (Fig. 4F).
DISCUSSION
The new observation that has emerged from our inves-
tigation is that cellular traffic into human renal allografts
causing acute rejection, a remediable risk factor for al-
lograft failure, can be identified noninvasively by mea-
surements of mRNA for the chemokine IP-10 and the
chemokine receptor CXCR3 in urinary cells.
A large number of chemokines are generated at sites of
inflammation, although differences in the tempo, cellular
source, and pattern of expression occur, partly relating to
the type of tissue and partly as to whether acute or chronic
injury is involved. On occasion, “spill-over” into the circu-
lation can be detected and may be of diagnostic or prog-
nostic significance. Thus, serum IP-10 levels are a good
indicator of disease activity in patients with various au-
toimmune diseases, including systemic lupus erythemato-
sus [27], new diagnosed type 1 diabetes [28], recent-onset
Grave’s disease [29], autoimmune liver diseases [30],
and relapsing remitting or secondary progressive multi-
ple sclerosis [31, 32]. Alhough absent in normal kidneys,
IP-10 hyperexpression within the kidneys of patients with
proliferative glomerulonephritis [33], and IP-10 produc-
tion by both human glomerular mesangial cells [33, 34]
and renal proximal tubular cells [35], following their
activation with interferon gamma (IFN-c) and tumor
necrosis factor-a (TNF-a), has been communicated. Ex-
perimental data are consistent with these reports, with IP-
10 expression detected in vivo during glomerulonephritis
[34, 36, 37] and tubulointerstitial nephritis [38, 39], and
production of IP-10 by mesangial [40–42], tubular [41,
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Fig. 4. Immunoperoxidase localization of interferon-inducible protein-10 (IP-10) and CXCR3 within representative renal biopsies of patients with
stable graft function or acute rejection. Sections were unstained with control monoclonal antibodies (A and B). IP-10 was expressed by occasional
interstitial cells (arrows) during stable renal function (C), but was strongly up-regulated within tubules and infiltrating mononuclear cells during
acute rejection (D); inset shows IP-10+ leukocytes crossing tubules. CXCR3 expression was absent during stable renal function (E) but was localized
to infiltrating mononuclear cells during acute rejection (F); inset shows several CXCR3+ leukocytes in varying stages of crossing a proximal tubule
(cryostat sections, hematoxylin counter-stain, original magnifications ×200 except insets ×750).
42], and interstitial fibroblast [42, 43] cells upon exposure
to cytokines in vitro.
Our study was stimulated in part by prior mechanistic
data as to the key roles of IP-10 [9] and CXCR3 [5] in
cardiac allograft rejection in mice, and on the evidence of
expression of this pathway during episodes of human car-
diac [10–12], lung [44], and liver [45] allograft rejection.
However, little is known as to IP-10 or CXCR3 expres-
sion during an episode of acute rejection of human renal
allografts. In the one report dealing with IP-10, Segerer
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et al [46] reported IP-10 mRNA expression within several
failed renal allografts. Similarly, in the only report regard-
ing CXCR3 expression during renal allograft rejection,
intragraft CXCR3+ leukocytes were detected during de-
velopment of transplant glomerulopathy in patients with
chronic allograft nephropathy [26].
Our analyses of urinary IP-10 and CXCR3 mRNA lev-
els indicate the utility of these genes as biomarkers of
acute renal allograft rejection. Measurement of IP-10
mRNA proved to be a particularly sensitive marker of
acute rejection, with 100% sensitivity. Measurement of
CXCR3 mRNA had a lower sensitivity (63%) for acute
rejection but a higher specificity (83% vs. 78%) than assay
of IP-10. This difference in sensitivity may reflect a delay
between the timing of chemokine production and shed-
ding of cells, including potentially tubular as well as host
inflammatory cells, and the subsequent recruitment and
transmigration of CXCR3+ mononuclear cells through
the graft and across the tubular cells (Fig. 4F, inset). Fur-
ther studies are required to assess the value of longitudi-
nal monitoring postrenal transplant, how mRNA levels
for these genes are modulated by antirejection therapy,
levels in patients experiencing vascular or mixed vascu-
lar and cellular rejection, and whether measurements of
mRNAs for IP-10 and CXCR3 provide diagnostic and/or
prognostic information capable of further refining non-
invasive diagnosis of acute rejection made by measure-
ments of mRNA for cytotoxic proteins granzyme B and
perforin [24]. Because IP-10 is expressed by tubular cells
as well as mononuclear cells and is an “invitational sig-
nal” for CXCR3 expressing CD4 T cells and because
granzyme B and perforin are prominently expressed by
CD8 T cells, measurements of urinary cell levels of IP-10
and CXCR3, as well as levels of granzyme B and perforin
may heighten the diagnostic accuracy.
In biopsies from patients without histologic or func-
tional evidence of acute rejection, as well as in several
donor nephrectomy samples, we detected minor IP-10
expression in association with small numbers of renal in-
terstitial cells, and no CXCR3 expression was detected.
By contrast, acute cellular rejection was accompanied
by dense staining for IP-10 of renal tubules and adja-
cent interstitial cells, plus infiltrating host mononuclear
cells. In addition, CXCR3 was localized to a subset of
host mononuclear cells, including in areas of tubulitis,
which is one of the diagnostic hallmarks of acute cellular
rejection. This tubular staining for IP-10, and the accom-
panying lymphocyte expression of the sole chemokine
receptor for IP-10 and CXCR3 during episodes of acute
rejection, provide a compelling explanation for the high
degree of accuracy in diagnosing acute rejection by mea-
surements of mRNA for IP-10 and CXCR3 in urinary
cells.
The first several months postrenal transplantation re-
main a critical period for development of acute rejection.
The development of noninvasive techniques for detection
of acute rejection and its differentiation from other causes
of graft dysfunction, including drug toxicity, ureteral com-
plications, infections, and disease recurrence, are major
goals of the transplantation community, especially since
the appropriate diagnosis and therapy may be of critical
import [47–49]. Multiple or ongoing but unrecognized in-
stances of low-level rejection (e.g., subclinical rejection)
are thought to determine long-term survival of an allo-
graft. The monitoring of chemokine and chemokine re-
ceptor genes such as described in this communication may
be an important new and noninvasive approach for the
detection of critical cellular traffic into the allografts and
also provide practical laboratory tools useful for the tai-
loring of immunosuppressive protocols.
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